Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

• Published in: Cancer research (Chicago, Ill.) Ill.), 2009-10, Vol.69 (20), p.7905-7910
• Main Authors: LEI XU, DUDA, Dan G, POLESKI, Martin, BENTLEY, Rex, CLARK, Jeffrey W, WILLETT, Christopher G, JAIN, Rakesh K, DI TOMATO, Emmanuelle, ANCUKIEWICZ, Marek, CHUNG, Daniel C, LAUWERS, Gregory Y, SAMUEL, Rekha, SHELLITO, Paul, CZITO, Brian G, LIN, Pei-Chun
• Format: Article
• Language: English
• Subjects: Antineoplastic agents; Biological and medical sciences; Gastroenterology. Liver. Pancreas. Abdomen; Medical sciences; Pharmacology. Drug treatments; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-09-2099

Clinical studies converge on the observation that circulating cytokines are elevated in most cancer patients by anti–vascular endothelial growth factor (VEGF) therapy. However, the source of these molecules and their relevance in tumor escape remain unknown. We examined the gene expression profiles of cancer cells and tumor-associated macrophages in tumor biopsies before and 12 days after monotherapy with the anti-VEGF antibody bevacizumab in patients with rectal carcinoma. Bevacizumab up-regulated stromal cell–derived factor 1α (SDF1α), its receptor CXCR4, and CXCL6, and down-regulated PlGF, Ang1, and Ang2 in cancer cells. In addition, bevacizumab decreased Ang1 and induced neuropilin 1 (NRP1) expression in tumor-associated macrophages. Higher SDF1α plasma levels during bevacizumab treatment significantly associated with distant metastasis at three years. These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy. [Cancer Res 2009;69(20):7905–10]